Sacroiliac Joint Fusion Market To Reach USD 4,106.7 Billion By 2032 | DataHorizzon Research
GlobeNewswire
The sacroiliac joint fusion market size was valued at USD 885.7 Billion in 2023 and is expected to reach a market size of USD..
National Institute of Neurological Disorders and Stroke
News and Video Search Results
News coverage
-
Inhibikase Therapeutics Issues Letter to Shareholders and Provides Update on Development Programs
GlobeNewswire
-
Alterity Therapeutics Parkinson’s Disease and Multiple System Atrophy Data Featured at the American Academy of Neurology (AAN) 2024 Annual Meeting
GlobeNewswire
-
Wistar Scientists Identify Pro-aging ‘Sugar Signature’ in the Blood of People Living with HIV
GlobeNewswire
-
U.S. Congressman Josh Gottheimer Champions Rare Disease Research With Sponsorship of Legislative Bill - H.Res.1039 - Advocating for Increased Funding for Charcot-Marie-Tooth Disease (CMT)
Business Wire
0 shares
1 views
You might like
National Institute of Neurological Disorders and Stroke media coverage
Congress Passes Bills Making Major Investments in Alzheimer’s
GlobeNewswire
Bill Increases Funding for Alzheimer’s Research and Prevention Efforts
WASHINGTON, March 23, 2024 (GLOBE NEWSWIRE) --..
-
LIXTE Provides Update on Progress with LB-100 as a PP2A Inhibitor to Enhance Chemotherapy and Immunotherapy Cancer Treatments
GlobeNewswire
-
Global Cerebral Oximetry Monitoring Market Size To Exceed USD 425.87 Million By 2033 | CAGR of 6.98%
GlobeNewswire
-
Biotechnology Industry Insights: Comprehensive Report on Collaboration Deals from 2019-2024 Now Available
GlobeNewswire
-
Pharmaceutical and Biotechnology Sector Insights: Comprehensive Analysis of Option and Evaluation Deals (2016-2024)
GlobeNewswire
Advertisement
More coverage
Fortress Biotech and Cyprium Therapeutics Announce $4.1 Million Grant from NINDS to Further Development of AAV-ATP7A Gene Therapy for Menkes Disease
GlobeNewswire
Encouraging preclinical studies demonstrate potential to combine AAV-ATP7A gene therapy with CUTX-101, which could be the first..
-
LIXTE Biotechnology Enters into Exclusive Immune Oncology Patent License Agreement with NINDS and NCI
GlobeNewswire
-
Biogen’s QALSODY® (tofersen), the First Therapy to Treat Rare, Genetic Form of ALS, Received Positive Opinion from CHMP
GlobeNewswire
-
Biogen Received European Commission Approval for SKYCLARYS® (omaveloxolone), the First Therapy to Treat Friedreich’s Ataxia
GlobeNewswire
-
ARMGO Pharma Publishes Positive Phase 1b Trial Results of Rycal® ARM210 for the Treatment of Ryanodine Receptor 1 Related Myopathies
GlobeNewswire